The primary goal of current treatment methods remains centered on symptom alleviation, achieved by making up for the loss of neurotransmitters, such as acetylcholine in Alzheimer’s disease using established cholinesterase inhibitors (ChEIs), and dopamine in Parkinson’s disease through the use of dopamine precursors or agonists; notably, ChEI medications like rivastigmine are also used to address cognitive decline in cases of Parkinson’s disease-related dementia (Reingold et al. 2007). Here, BCHE is linked to Alzheimer disease.